Tracers / [125I]I-Ex-4
[125I]I-Ex-4
- Radionuclide
- I-125 t½ 85666 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Exendin-4 peptide analogue (GLP-1 receptor agonist)
- Target / mechanism
- GLP-1 receptor (GLP-1R) agonist PMID 40076236
- Clinical application
- GLP-1R imaging, with hypoglycemia risk particularly relevant in insulinoma patients PMID 40076236
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | 54% | >99% | Ex-4-C40 | 40076236 2025 Molecules For radiolabeling peptides, [125I]IPM in acetonitrile was reacted with Ex-D3-C40, Ex-4-C40, or Ex-F1-C40 (100 μg dissolved in PBS) for 30 min at room temperature. — The radiochemical yields for [125I]I-Ex-D3, [125I]I-Ex-4, and [125I]I-Ex-F1 were 43%, 54%, and 59%, respectively |
Need this precursor?We can point you to suppliers for [125I]I-Ex-4, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40076236. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40076236: 'Ex-D3-C40, Ex-4-C40, or Ex-F1-C40 were dissolved in PBS (pH 7.4) and added with IPM (1 eq.) to acetonitrile.'.